DNA Biomed Solns (DNA) - Total Liabilities
Based on the latest financial reports, DNA Biomed Solns (DNA) has total liabilities worth ILA1.77 Million ILA (≈ $4.76K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore DNA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
DNA Biomed Solns - Total Liabilities Trend (2005–2024)
This chart illustrates how DNA Biomed Solns's total liabilities have evolved over time, based on quarterly financial data. See DNA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
DNA Biomed Solns Competitors by Total Liabilities
The table below lists competitors of DNA Biomed Solns ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Impresa - Sociedade Gestora de Participações Sociais S.A
LS:IPR
|
Portugal | €250.78 Million |
|
Fortune Bay Corp
V:FOR
|
Canada | CA$1.89 Million |
|
Rekah Pharmaceutical Industry Ltd
TA:REKA
|
Israel | ILA279.47 Million |
|
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
|
USA | $166.27 Million |
|
Denge Yatirim Holding AS
IS:DENGE
|
Turkey | TL576.37 Million |
|
Xreality Group Ltd
AU:XRG
|
Australia | AU$37.23 Million |
|
Level Biotechnology
TWO:3118
|
Taiwan | NT$237.03 Million |
|
Sharps Technology Inc
NASDAQ:STSS
|
USA | $10.75 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down DNA Biomed Solns's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DNA Biomed Solns stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 48.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DNA Biomed Solns's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DNA Biomed Solns (2005–2024)
The table below shows the annual total liabilities of DNA Biomed Solns from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA2.81 Million ≈ $7.55K |
+91.37% |
| 2023-12-31 | ILA1.47 Million ≈ $3.94K |
-21.84% |
| 2022-12-31 | ILA1.88 Million ≈ $5.05K |
+555.75% |
| 2021-12-31 | ILA287.00K ≈ $769.44 |
-97.28% |
| 2020-12-31 | ILA10.54 Million ≈ $28.27K |
+23.30% |
| 2019-12-31 | ILA8.55 Million ≈ $22.92K |
-45.92% |
| 2018-12-31 | ILA15.81 Million ≈ $42.39K |
+75.94% |
| 2017-12-31 | ILA8.99 Million ≈ $24.09K |
-92.61% |
| 2016-12-31 | ILA121.59 Million ≈ $325.97K |
+236.83% |
| 2015-12-31 | ILA36.10 Million ≈ $96.77K |
+30.42% |
| 2014-12-31 | ILA27.68 Million ≈ $74.20K |
+201.03% |
| 2013-12-31 | ILA9.19 Million ≈ $24.65K |
-4.97% |
| 2012-12-31 | ILA9.68 Million ≈ $25.94K |
+51.84% |
| 2011-12-31 | ILA6.37 Million ≈ $17.08K |
-29.79% |
| 2010-12-31 | ILA9.08 Million ≈ $24.33K |
+35.44% |
| 2009-12-31 | ILA6.70 Million ≈ $17.97K |
-16.97% |
| 2008-12-31 | ILA8.07 Million ≈ $21.64K |
+49.13% |
| 2006-12-31 | ILA5.41 Million ≈ $14.51K |
+68.02% |
| 2005-12-31 | ILA3.22 Million ≈ $8.64K |
-- |
About DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more